2026 International Spring Forum
April 15, 2026 | 12:00 PM EST
- Home
- Clinical Resources Search
- PQI in Action: ClonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma
ClonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma
About this PQI in Action
In an effort to promote higher quality patient care, NCODA created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance resource for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients. This article will explore the PQI in patients who are monitored with minimal residual disease (MRD) testing. This PQI in Action is a follow up to the clonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma PQI and explores how the medically integrated teams at Florida Cancer Specialists & Research Institute (FCS) and Rocky Mountain Cancer Centers incorporate the information found in the PQIs as part of their daily workflow. This article will discuss how utilizing the clonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma PQI elevates patient care.
More About This PQI in Action
Find a PQIPQI
PQI: clonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma
Last Updated: 01/08/2024 12:00 am
PQI
PQI: clonoSEQ® Next Generation Sequencing for Minimum Residual Disease Testing in Chronic Lymphocytic Leukemia
Last Updated: 01/08/2024 12:00 am